Received Nov 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | NA4452 | IM / LA |
The patient presented for covid 19 and influenza immunizations. Consent forms were reviewed prior to vaccination and all screening question were answered in the negative. Per record, the patient previously received Pfizer Covid 19 vaccinations, with the most recent dose administered in 2022. The Pfizer Comirnaty vaccine was administered 11/7/2025. Shortly after administration, the patient exhibited brief seizure-like activity lasting very briefly. The patient regained responsiveness promptly and reported dizziness and nausea. the patient experienced two episodes of vomiting, after which he reported feeling slightly better. I remained with the patient throughout the entire event and continued close observation. An EpiPen was prepared and kept at the side. However administration was not indicated as the patient maintained normal respiratory effort. Emergency medical services were contacted, and paramedics arrived on site. the Patient s vital signs were assessed and found to be with normal limits, with the exception of mildly decrease blood pressure. The patient remained alert and oriented and was able to walk on his own power. The patient expressed a desire to be evaluated at the hospital. The patient walked on his own power, supported by his accompanying friend and monitored closely by paramedics, from the immunization room to the ambulance for transport.
not listed
not listed at time of vaccination
no
not listed on consent form
vital signs were obtained by paramedics